Related Experiment Video
Updated: Aug 6, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Balancing Act: The Dual Roles of BAFF in Systemic Lupus Erythematosus
Jhonatan Antonio Álvarez-Gómez1, Daniel Appelgren2, Tomas Walhelm3
1Division of Inflammation & Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. jhonatan.antonio.alvarez.gomez@liu.se.
B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are key in autoimmune diseases. This review examines their complex role in regulatory B cells and the effectiveness of therapies targeting them.
Area of Science:
- Immunology
- Rheumatology
- Cell Biology
Background:
- B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are crucial cytokines in regulating B cell survival and differentiation in autoimmune diseases like systemic lupus erythematosus (SLE).
- These cytokines interact with receptors BAFF-Receptor (BAFF-R), TACI, and BCMA, influencing self-reactive B cells and antibody production.
- Current biologic therapies targeting BAFF/APRIL show variable efficacy and safety profiles, with some cases of de novo lupus nephritis observed despite treatment.
Purpose of the Study:
- To review current evidence on anti-BAFF/APRIL therapies in autoimmune diseases.
- To explore the complex and potentially context-dependent role of BAFF in the function and development of regulatory B cells (Bregs).
- To address the unresolved question of whether BAFF's involvement in regulatory immune responses is beneficial or detrimental.
Main Methods:
- Literature review of existing studies on BAFF, APRIL, and their targeted therapies.
- Analysis of clinical trial data and observational studies concerning belimumab and other anti-BAFF/APRIL agents.
- Examination of the molecular interactions between BAFF/APRIL, their receptors, and B cell subsets, including Bregs.
Main Results:
- Anti-BAFF/APRIL therapies can lead to profound B cell suppression and reduced immunoglobulin production.
- Belimumab has shown efficacy in SLE but has been associated with de novo lupus nephritis in some patients.
- Belimumab treatment correlates with reduced regulatory B cell markers and IL-10 levels, suggesting a role for BAFF in Breg function.
Conclusions:
- The precise role of BAFF in supporting regulatory B cell function remains complex and requires further elucidation.
- Understanding BAFF's context-dependent effects is critical for optimizing therapeutic strategies in autoimmune diseases.
- Further research is needed to fully unravel the intricate interplay between BAFF, APRIL, and the regulatory immune system.
Related Concept Videos
Functions of the Lymphatic and Immune System
The primary lymphoid organs, including the bone marrow and the thymus, serve as the maturation sites for lymphocytes. Secondary lymphoid organs, like the mucosa-associated lymphoid tissue, activate these lymphocytes and serve as...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Secondary Lymphoid Organs
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Nephrotic Syndrome II : Assessment and Medical Management
